BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
BC Extra | Dec 9, 2019
Company News

With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race

With its proposed acquisition of ArQule, Merck will join the ranks of at least three other pharmas adding Btk inhibitors to their portfolios while appearing to pay much less than its peers. The $2.7 billion...
BC Extra | Nov 6, 2019
Clinical News

Lilly, ArQule jockey for best-in-class next-gen Btk inhibitor at ASH

While investors punished ArQule on Phase I data for ARQ 531, the Bruton’s tyrosine kinase inhibitor was tested in a slightly sicker population than Lilly's competing LOXO-305, and each company used different endpoints, making it...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

Biotech watchers are hoping a busy fourth quarter of data readouts, regulatory actions and IPOs will provide some bright spots to counteract the sector’s continued overall underperformance, which is not expected to improve in 2020....
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Week In Review | Aug 17, 2017
Clinical News

ArQule begins Phase I of ARQ 531 in B cell malignancies

ArQule Inc. (NASDAQ:ARQL) began a Phase I trial to evaluate once-daily oral ARQ 531 for 4 weeks in patients with relapsed or refractory B cell malignancies. The trial's dose-escalation first portion will test ARQ 531...
Items per page:
1 - 7 of 7